Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acefylline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acefylline SCHEMBL356114 | 1.00 | ADORA2B (0.85) | ADORA2BSMN1; SMN2KMT2AMEN1LMNA | |
| Acefylline SCHEMBL18191994 | 0.92 | ADORA2B (1.00) | ADORA2BSMN1; SMN2KMT2AMEN1LMNA | |
| Acefylline SCHEMBL308514 | 0.92 | ADORA2B (1.00) | ADORA2BSMN1; SMN2KMT2AMEN1LMNA | |
| Acefylline SCHEMBL8402147 | 0.91 | ADORA2B (0.97) | ADORA2BSMN1; SMN2KMT2AMEN1LMNA | |
| Acefylline SCHEMBL1173152 | 0.87 | ADORA2B (0.89) | ADORA2BSMN1; SMN2KMT2AMEN1LMNA | |
| Acefylline SCHEMBL17204841 | 0.84 | ADORA2B (0.84) | ADORA2BSMN1; SMN2KMT2AMEN1LMNA | |
| Acefylline SCHEMBL8976498 | 0.84 | ADORA2B (0.66) | ADORA2BSMN1; SMN2KMT2AMEN1RXFP1 | |
| SCHEMBL17163939 | 0.81 | ADORA2B (0.78) | ADORA2BSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL11531219 | 0.81 | ADORA2B (0.78) | ADORA2BSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL18166629 | 0.80 | RXFP1 (0.80) | ADORA2BSMN1; SMN2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| US-20040049022-A1 | Composition & methods for treatment and screening | NYCE JONATHAN W (US) | 2004-03-11 | — | — | US | claimed |
| WO-2004011613-A2 | COMPOSITION & METHODS FOR TREATMENT AND SCREENING | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | claimed |
| JP-2003517428-A | — | — | 2003-05-27 | — | — | JP | claimed |
| US-20030087845-A1 | COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION & TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION | EPIGENESIS PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | claimed |
| WO-2002085309-A2 | COMPOSITION, FORMULATIONS & KITS FOR TREATMENT OF RESPIRATORY & LUNG DISEASE WITH ANTI-SENSE OLIGONUCLEOTIDES & A BRONCHODILATING AGENT | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | claimed |
| EP-1011608-A4 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | EPIGENESIS PHARMACEUTICALS INC (US) | 2002-05-15 | — | — | EP | claimed |
| EP-1019065-A4 | MULTIPLE TARGET HYBRIDIZING NUCLEIC ACIDS, THEIR PREPARATION, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS | UNIV EAST CAROLINA (US) | 2002-02-20 | — | — | EP | claimed |
| EP-1168919-A2 | LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE, COMPOSITIONS, KIT AND METHOD FOR TREATMENT OF AIRWAY DISORDERS ASSOCIATED WITH BRONCHOCONSTRICTION, LUNG INFLAMMATION, ALLERGY(IES) AND SURFACTANT DEPLETION | East Carolina University (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2000062736-A2 | LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE, COMPOSITIONS, KIT AND METHOD FOR TREATMENT OF AIRWAY DISORDERS ASSOCIATED WITH BRONCHOCONSTRICTION, LUNG INFLAMMATION, ALLERGY(IES) AND SURFACTANT DEPLETION | EAST CAROLINA UNIVERSITY (US) | 2000-10-26 | — | — | WO | claimed |
| EP-1019065-A1 | MULTIPLE TARGET HYBRIDIZING NUCLEIC ACIDS, THEIR PREPARATION, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS | EAST CAROLINA UNIVERSITY (US) | 2000-07-19 | — | — | EP | claimed |
| EP-1011608-A2 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | Epigenesis Pharmaceuticals, Inc. (US) | 2000-06-28 | — | — | EP | claimed |
| WO-1999063938-A9 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | EPIGENESIS PHARMACEUTICALS INC (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999063938-A2 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | EPIGENESIS PHARMACEUTICALS, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1999013886-B1 | MULTIPLE TARGET HYBRIDIZING NUCLEIC ACIDS, THEIR PREPARATION, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS | UNIV EAST CAROLINA (US) | 1999-04-22 | — | — | WO | claimed |
| WO-1999013886-A1 | MULTIPLE TARGET HYBRIDIZING NUCLEIC ACIDS, THEIR PREPARATION, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS | EAST CAROLINA UNIVERSITY (US) | 1999-03-25 | — | — | WO | claimed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | disclosed |
| US-7034007-B1 | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion | EAST CAROLINA UNIVERSITY (US) | 2006-04-25 | — | — | US | disclosed |
| WO-1999063938-A2 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | EPIGENESIS PHARMACEUTICALS, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999013886-A1 | MULTIPLE TARGET HYBRIDIZING NUCLEIC ACIDS, THEIR PREPARATION, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS | EAST CAROLINA UNIVERSITY (US) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087845-A1 | COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION & TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885SMN1; SMN2 1703/4885KMT2A 3396/4885 |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | ADORA2B 15/4885SMN1; SMN2 3963/4885KMT2A 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.